Napabucasin Failure Costly, And Possibly Transformative, For Dainippon
Latuda Expiry Also Looming
Japanese firm’s recent decision to halt development of its lead oncology asset, gained through a multi-billion-dollar acquisition where it was the main attraction, not only has a financial cost but may prompt more strategic deal-making.
You may also be interested in...
Myovant’s Relugolix Won’t Be Stopped By Missed Endpoint
The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.
Myovant's Relugolix Shows Promising Profile For Endometriosis Pain
The first Phase III trial testing relugolix combination therapy in endometriosis pain showed efficacy with minimal bone mineral density loss, an issue with AbbVie's rival drug Orilissa. An US NDA was also filed in prostate cancer.
M&A A Major Pillar Of Sumitomo Dainippon's New Mid-Term Plan
Mid-size Japanese player Sumitomo Dainippon sets aside billions for potential M&A deals under a new business plan designed to fill gaps in its neurology pipeline as it prepares to lose exclusivity for its top global product.